This indicates that in the real-world setting, the efficacy of dabrafenib combined with trametinib in patients with advanced NSCLC and BRAF V600 mutation is similar to that observed in previous clinical trials.22 This evidence concerns the gene BRAF and non-small cell lung carcinoma.